PositiveSelect™

Positive Bioscience

| Patient | | Physician | |
|---|---|---|---|
| Name : xxxxxxxxxx | | Name : xx xxxxxxxxx | |
| Gender : M | Date of Birth : DD/MM/YYYY | Institute : xxxxxxxxxx | |

**Diagnosis : Adenocarcinoma of Colon**

| | | | |
|---|---|---|---|
| Sample Type : FFPE | Sample Collection Date : DD/MM/YYYY | | Sample ID : PB_CG_SC_XXXX-XX_X |
| Test : PositiveSelect CRC | Technology : Illumina NGS | Coverage : 1000x | Report Date : DD/MM/YYYY |

## Patient Tumor Type Specific Genes

| Gene | Genetic Alteration | Result |
|---|---|---|
| BRAF Mutation [p.V600E] | No alteration detected | Negative |
| KRAS Mutation [Exon 2] | [c.35G>A, p.G12D] | Positive |
| KRAS Mutation [Exon 2, 3, 4] | No alteration detected | Negative |
| MLH1 Mutation | No alteration detected | Negative |
| MSH2 Mutation | No alteration detected | Negative |
| MSH6 Mutation | [c.467C>A, p.Ser156Ter] | Positive |
| NRAS Mutation [Exon 2, 3, 4] | No alteration detected | Negative |

* Note: MSH6 [c.467C>A] mutation identified in this patient has been classified as pathogenic by ACMG [American College of Medical Genetics and Genomics]. Another variant at the same position MSH6 c.467C>G [p.Ser156Ter] has been regarded pathogenic as per ClinVar, however the identified mutation in the patient [c.467C>A, p.Ser156Ter] also results in premature stop codon. Thus the identified mutation may also result in similar effects as [c.467C>G] due to protein truncation.

Note: Genomic alterations in the 6 genes related to cancer type (Colorectal Cancer) as listed in NCCN guidelines are reported here.



**Positive Biosciences Ltd.**
**Registered Office**: 645, Anna Salai, Thousand Lights, Chennai - 600 006. Tel.: 044-28290187
**Corporate Office**: 1st Floor, Kohinoor City Mall, Gate No. 1, Opp. Don Bosco School, Premier Road, Kirol Road, Kurla (West), Mumbai - 400 070.
Toll Free: 1800 1235 835 Website: www.positivebioscience.com Email: info@positivebioscience.com CIN: U93000TN1995PLC030290

PositiveSelect™

Positive Bioscience

## About PositiveSelect CRC

PositiveSelect CRC is a targeted-NGS based diagnostic test, which tests for all four categories of genomic alterations; single nucleotide variations,inde ls, co py number variation s, structural variations, in the 6 gene s as listed a bove. It ad ds the advan tage of mak ing av ailable a compreh ensive molecular tes ting solutio n as indica ted in the guideli nes with spe cificity and se nsitivity higher than the conventional platforms.

The PositiveSelect CRC test, has been designed to work both on FFPE and liquid biopsy, thus ensuring the criteria for sample procurement and requirement is made convenient. The blood collection tube that comes with the test, ensures low risk of sample degradation and extraction of adequate ctDNA for the test. The custom-designed assay enriches all the 6 recommended gene targets from the cfDNA and further is sequenced in a depth of 1000X on the Next- Seq Illumina NGS platform. The end result involves massive parallel sequencing of all the enriched cancer-specific target regions along with flanking introns.

Analyzed by:

Scientific Officer

Verified by:

Sr. Scientific Officer





**Positive Biosciences Ltd.**

**Registered Office**: 645, Anna Salai, Thousand Lights, Chennai - 600 006. Tel.: 044-28290187

**Corporate Office**: 1st Floor, Kohinoor City Mall, Gate No. 1, Opp. Don Bosco School, Premier Road, Kirol Road, Kurla (West), Mumbai - 400 070.

Toll Free: 1800 1235 835 Website: www.positivebioscience.com Email: info@positivebioscience.com CIN: U93000TN1995PLC030290